ArticleACS central science2019
Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography.
Article in ACS central science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Ferroptosis-related stress during aging and its relevance to disease.GeroScience · 2026Review
- Article
- Three decades of selective product formationRSC advances · 2025Review
- Ironing out the details of ferroptosis.Nature cell biology · 2024Review
- A tandem activity-based sensing and labeling strategy reveals antioxidant response element regulation of labile iron pools.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- In vivo bioluminescence imaging of labile iron in xenograft models and liver using FeAL-1, an iron-activatable form of D-luciferin.Cell chemical biology · 2023Article
- Imaging-Selected Host Responses in the Context of Infections.The Journal of infectious diseases · 2023Article
- Simultaneous FeScience advances · 2023Article
- Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac/kidney injuries.Science advances · 2023Article
- Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy.European journal of medicinal chemistry · 2023Article
- Visualization of ferroptosis in brain diseases and ferroptosis-inducing nanomedicine for glioma.American journal of nuclear medicine and molecular imaging · 2023Review
- Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology.Signal transduction and targeted therapy · 2022Review
- Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.The Journal of experimental medicine · 2022Article
- Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.The Prostate · 2022Review
- Iron homeostasis and organismal aging.Ageing research reviews · 2021Review
- Expanded scope of Griesbaum co-ozonolysis for the preparation of structurally diverse sensors of ferrous iron.RSC advances · 2021Article
- Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Epigenomic regulation by labile iron.Free radical biology & medicine · 2021Article
- Integrin αCancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Ferrous Iron-Dependent Pharmacology.Trends in pharmacological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Redox cycling of iron powers various enzyme functions crucial for life, making the study of iron acquisition, storage, and disposition in the whole organism a worthy topic of inquiry. However, despite its important role in biology and disease, imaging iron in animals with oxidation-state specificity remains an outstanding problem in biology and medicine. Here we report a first-generation reactivity-based probe of labile ferrous iron suitable for positron emission tomography studies in live animals. The responses of this reagent to systemic changes in labile iron disposition were revealed using iron supplementation and sequestration treatments in mice, while the potential of this approach for in vivo imaging of cancer was demonstrated using genetically and pathologically diverse mouse models, including spontaneous tumors arising in a genetically engineered model of prostate cancer driven by loss of PTEN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.